Indiana PA Criteria Training

PA Type	Criteria	PA Approval	Worked By
Actiq PRESCRIBER MUST REQUEST PA PHONE OR FAX	PA Requirements Patient must: 1. Have a diagnosis of Cancer AND 2. Be under the care of an Oncologist, Pain Specialist, or in a hospice setting AND 3. Currently be on a fentanyl (Duragesic) patch AND 4. Be NPO (no meds by mouth/orally) with a non-functioning enteral tube OR 5. Have a medically justifiable diagnosis associated with moderate to severe pain (updated info as of 6/25/2004).	Length 6 months	Pharmacy Tech or escalate to Clinical RPh for review of DX if needed
Acetaminophen limits (3gms/day) PRESCRIBER MUST REQUEST PA PHONE ONLY	PA requirements Approval will be granted only if: 1. Requested duration of therapy is no more than 10 days 2. Requested quantity does not exceed 4gms acetaminophen/day 3. Patient has not received a similar override in previous 3 months	One time approval only for 10 days supply; only one approval may be given in a 3 month period	
Wound Care PRESCRIBER MUST REQUEST PA	PA Requirements Approval will be granted if the following criteria is met: 1. Medication is requested to treat an active wound, not being used as prophylaxis or as a protective barrier. 2. Patient has been treated previously with one or more of the preferred medications	3 months (quantity must be entered on PA= 3	

РА Туре	Criteria	PA Approval Length	Worked By
PHONE ONLY	Regranex: 1. Patient must be a diabetic (system will automatically approve if diabetic medication noted in history) 2. There is a limit of one tube per 30 days. If there are multiple wound sites, we should approve one time only for one tube.	standard manufacturers package i.e. 60gm tube x 3 =180)	
Brand Medically Necessary PRESCRIBER MUST REQUEST PA FAX	PA Requirements Includes only brand name drugs that have multiple "sources" or multiple generics available, are federal legend drugs, and that have a federal upper limit (FUL) or maximum allowable charge (MAC) pricing. Only drugs that meet these requirements are subject to the BMN PA program Procedure How to Determine PA Requirements for BMN If a drug is branded, has multiple sources, is federal legend AND has innovator of "yes", the "PA Requirements" screen will show that PA is required for BMN. REQUIRED, regardless of what is indicated on the PA Requirements indicator. If there is no MAC/FUL pricing, the claims should pay after the pharmacist keys a dispense-aswritten (DAW) or "06" override. If it is a branded drug with multiple sources, is a federal legend drug, has an innovator of yes, requires PA on the PA requirements for BMN, and has MAC pricing, BUT is listed by generic name on the "PA Except" list - it does not require PA. The claims should pay after the pharmacist keys a dispense-as-written (DAW) or "06" override.	1 year	Pharmacy Tech

PA Type	Criteria	PA Approval Length	Worked By
	are only used when the prescriber substantiates the medical necessity for the brand name product. Patient requests for brand name products will not be sufficient for granting prior approval. Applicability Criteria Allergic reaction to the excipients in the generic products OR Therapeutic failure to the generic product Drug shortages are a reason for short term approval of brand name products (3-month approval) Physician must write "Brand Medically Necessary" in own handwriting on original script and request PA for any drugs that require prior authorization. It is the responsibility of the prescribing physician to submit a MedWatch form to the FDA for all Brand Medically Necessary medication requests. The prescriber must include a copy of the completed MedWatch form to ACS with their request. ACS State Healthcare must authorize brand name drugs that are subject to the Preferred Drug List. *****If the drug requested is also considered Non-PDL, 2 PAs must be entered for the drug*****		
	 Exempted Drugs All mental health/cross-indicated drugs per 405 IAC 5-24-8.6 Coumadin, Dilantin, Lanoxin, Premarin, Provera, Synthroid, Tegretol per BT200132 Physician must write on DAW side of script (sign on left) and write "Brand Medically Necessary" in own handwriting directly on prescription. Pharmacy must use DAW 06 to override. 		

PA Type	Criteria	PA Approval Length	Worked By
Cox II Inhibitors and Brand-Only NSAIDs PRESCRIBER MUST REQUEST PA PHONE OR FAX	Approval Requirements for Cox II Inhibitors No PA required for patients over 70 years of age. Anticoagulant therapy- auto-approve History of serious NSAID induced complications (GI bleed, moderate to severe GERD, PUD, or allergic reaction) OR Failure of 2 separate two-week trials of generically available NSAIDs OR GI risk score of 13 points or higher (fax request preferred) OR Aspirin allergy OR Currently on chemotherapy, have kidney failure, or a history of Crohn's Disease. Purpose Encourage step-therapy between classes of NSAIDs before use of more expensive brandname products. COX-2 Inhibitors Colecoxib (Celebrex) Approval Requirements for Brand-Only NSAIDs It is the responsibility of the prescribing physician to submit a Med Watch form to the FDA for all Brand-Only NSAID requests. If the request is for Arthrotec and there is documented failure of 2 generic NSAID trials and the patient has a GI Risk Score of 13 or higher, the PA request can be approved. If the request is for Mobic, Ponstel, or any other NSAID that has no generic equivalent and there is documented failure of 2 generic NSAID trials, the PA request can be approved.	1 Year	Pharmacy Tech

PA Type			Criteria		PA Approval Length	Worked By
	name products. Brand-Only NSAIDs Mobic (Melo Ponstel (Meforal Arthrotec (Mefora) Arthrotec (Mefora) Arthrotec (Mefora) Arthrotec (Mefora) Arthrotec (Mefora) Arthro	exicam)- Patients m enamic)- Patients n isoprostol/Diclofen core of 13 points or	ust fail 2 generic sourd nust fail 2 generic sour nac)- Patients must fail	te of more expensive brand- te NSAIDs (No GI Benefit) rce NSAIDs (No GI Benefit) 2 generic source NSAIDs and		
	C 'N	-				
	Generic Name	Brand Name	Generic Name	Brand Name		
	DiclofenacPotassium	Cataflam	Keto <u>pro</u> fen	Orudis		
	Diclofenac Sodium	Voltaren	Meclofenamate	Meclomen		
	Etodolac	Lodine	Na <u>proxe</u> n	Naprosyn		
	Fenoprofen Calcium	Nalfon	Naproxen Sodium	Anaprox		
	Flurbiprofen	Ansaid	Ne <u>bum</u> atone	Relafen		
	Indo <u>meth</u> acin	Indocin	Oxa <u>proz</u> in	Daypro		
	Ibu <u>prof</u> en	Motrin	Pi <u>roxi</u> cam	Feldene		
	<u>Sul</u> indac	Clinoril	Tolmetin	Tolectin		

Patient's Risk Criteria	PA Type	Criteria	PA Approval Length	Worked By
		Patient's Risk Criteria Current Health Status (Select only one Category) No restrictions of ability to perform normal activities = 0 points Moderate restriction, but with an ability to perform most activities of daily living and occupation = 1 points Marked restrictions, with an inability to perform most activities of daily living and occupation = 2 points Incapacitation with confinement to bed or wheelchair = 3 points How frequent has the patient experienced NSAID induced GI Side Effects? Never = 0 points Occasional = 4 points Frequent = 5 points How is the patient currently using their NSAIDs? No = 0 points RX/Constant Use = 1 point Is the patient taking concurrent Oral Steroids? No = 0 points Yes = 4 points Patients Age and Points Patients Age and Points 225 years = 0 points 41-45 years = 4 points 31-35 years = 2 points 56-60 years = 7 points 56-60 years = 7 points		

PA Type	Criteria	PA Approval Length	Worked By
Drug-Drug Interaction PRESCRIBER MUST REQUEST PA PHONE OR FAX	PA Approval Requirements Drug – Drug exists because of discontinued medication Clinical rationale or extenuating circumstances documented and provided Contacting provider is the prescriber Purpose To identify patients potentially exposed to a severity 1 drug interaction.	For DD needed due to discontinued medication: approve for 5 months from the last fill date of discontinued medication.	Clinical RPh
		For all other reasons, approve for 1 year or life of therapy based on reviewing pharmacist's discretion.	
Early Refill PRESCRIBER OR PHARMACY MAY REQUEST PA	Purpose Prevent fraud and waste by not allowing refills until at least 75% of medication is taken. Applicability All drugs are subject to this edit. Retail Locations	Approved PA entered in for 1 day – date of service – pharmacy must fill prescription	Pharmacy Tech

PA Type	Criteria		PA Approval Length	Worked By
PHONE OR FAX	and you verify in claims incorrect days supply Patient has lost medication Approve Medication was stolen Approve (check PA his Recommend police reportequired. Patient spilled medication in trash, toilet, sink, etc Patient is going on vacation Approve 1 month, if more supplied to the provided supplied supplied to the provided supplied to the provided supplied sup	and pharmacy can fill on that date	on that day only.	
	- Long Term Care IF THEN Dose has changed Approve Pharmacy has entered wrong days supply and you verify in claims			

PA Type		Criteria	PA Approval Length	Worked By
	Nursing home has lost medication Pharmacy is taking on new Nursing home and want to do a one time roll over for all patients New Admit or Re Admit Nursing home spilled medication Patient is going LOA School or work supply Nursing home returned by mistake Med Cart Stolen from nursing home Patient has a PRN order and a routine order with different RX numbers	Deny, Nursing home responsible for cost Deny, Nursing Facility Administration should ensure a transition than does not waste taxpayer funded medication. Approve Approve Approve Deny. It can just be sent out again. Pharmacy has already been paid. Approve after verifying with nursing home administrator. Escalate to supervisor. Approve		
Forteo PRESCRIBER MUST REQUEST PA PHONE OR FAX	osteoporosis AND 2. The patient has failed or been in The answer must be yes to one out of two	teoporosis or men with primary or hypogonadal tolerant of previous osteoporosis therapy. vo of the below questions to qualify for Forteo: neral density T score less than –2.5? osteoporotic fracture? ders the patient ineligible for Forteo: sease of bone?	1 year The duration of therapy is 24 months per lifetime.	Pharmacy Tech

PA Type	Criteria	PA Approval Length	Worked By
	 3. Has the patient had prior radiation therapy involving the skeleton? 4. Does the patient have bone metastases or skeletal malignancies? 5. Does the patient have a metabolic bone disease other than osteoporosis? 6. Does the patient have pre-existing hypercalcemia (Ca++ > 12mg/dL)? 		
Growth Hormones	PA Requirements Growth Hormone Deficiency (new start)	1 year	Pharmacy Tech or escalate to
PRESCRIBER MUST REQUEST PA	 Deviation of 2.0 standard deviations or more below mean height for age prior to therapy (growth chart) No expanding intracranial lesions or tumor (MRI or preferably written 		Clinical RPh for review if
FAX ONLY	 documentation) 3. Growth rate of 5cm/yr or less before start of therapy 4. Failure of 2 stimuli tests to levels about 10ngm/ml before start of therapy 5. Bone age of 14-15 or less in females, 15-16 or less in males (x-ray or preferably written documentation) 		DX is something other than the curren criteria
	 6. 6. Epiphyses open (x-ray or preferably written documentation). Documented evidence of open epiphyses needed only if patient is nearing puberty (estimated age range 10 – 16 years of age). 7. 7. Patient must be under 18 years old 		based diagnoses listed
	 Growth Retardation with Chronic Renal Insufficiency 1. Deviation of 2.0 standard deviations or more below mean height for age prior to therapy (growth chart) 2. No expanding intracranial lesions or tumor (MRI or preferably written 		

PA Type	Criteria	PA Approval Length	Worked By
	 documentation) 3. Growth rate of 5cm/yr or less at start of therapy 4. Irreversible renal insufficiency with creatinine clearance less than 75mL/min per 1.73m2 5. Bone age 14-15 or less in females, 15-16 or less in males (x-ray or preferably written documentation) 6. Epiphyses open (x-ray or preferably written documentation). Documented evidence of open epiphyses needed only if patient is nearing puberty (estimated age range 10 – 16 years of age). 		
	 Turner's Syndrome 1. Chromosomal abnormality showing Turner's syndrome 2. Deviation of 2.0 standard deviations or more below mean height for age prior to therapy (growth chart) 3. No expanding intracranial lesions or tumor (MRI or preferably written documentation) 4. Growth rate 5cm/year or less at start of therapy 5. Bone age of 14-15 or less in females, 15-16 or less in males (x-ray or preferably written documentation) 6. Epiphyses open (x-ray or preferably written documentation). Documented evidence of open epiphyses needed only if patient is nearing puberty (estimated age range 10 – 16 years of age). 		
	Neurosecretory Growth Retardation 1. 1. Deviation of 2.0 standard deviations or more below mean height for age prior to		

PA Type	Criteria	PA Approval Length	Worked By
	 therapy (growth chart) No expanding intracranial lesions or tumor (MRI or preferably written documentation) Growth rate of 5cm/year or less at start of therapy Bone age of 14-15 or less in females, 15-16 or less in males (x-ray or preferably written documentation) Epiphysis open (x-ray or preferably written documentation). Documented evidence of open epiphyses needed only if patient is nearing puberty (estimated age range 10 – 16 years of age). Mixed or normal response to any two stimuli test IGF-1 levels less than 50th percentile for chronological age all re-authorizations, the only requirements needed are generally the current growth rate and bone age. Current x-rays or current written documentation will be required for patients nearing puberty to assess whether or not epiphyses are open. 		
Peptic Acid	<u>Purpose</u>	1 year	Pharmacy

PA Type	Criteria	PA Approval Length	Worked By
Medications (Carafate and Cytotec) PRESCRIBER MUST REQUEST PA PHONE OR FAX	Lowest sustainable acid suppression Avoiding duplicative therapy between acid suppression drugs and Carafate or Cytotec Applicability Cytotec, Carafate Carafate (Sucralfate) Indicated for open wounds (i.e. Ulcer) within the GI tract Considered duplicate therapy when prescribed concurrently with other peptic acid drugs beyond initial 30-days and will not be approved. Will not be authorized for GERD Maintenance dose of 1 gram BID does not require PA Cytotec Indicated only for the prevention of side effects associated with use of NSAIDs. Must meet GI risk of 13 points Considered duplicative therapy when prescribed concurrently with other peptic acid drugs and will not be approved.		Tech

Patient's Risk Criteria	PA Type	Criteria	PA Approval Length	Worked By
		Patient's Risk Criteria Patient's Points Current Health Status (Select only one Category) No restrictions of ability to perform normal activities = 0 points Moderate restriction, but with an ability to perform most activities of daily living and occupation = 1 points Marked restrictions, with an inability to perform most activities of daily living and occupation = 2 points Incapacitation with confinement to bed or wheelchair = 3 points How frequent has the patient experienced NSAID induced GI Side Effects? Never = 0 points Occasional = 4 points Frequent = 5 points How is the patient currently using their NSAIDs? No = 0 points RX/Constant Use = 1 point Is the patient taking concurrent Oral Steroids? No = 0 points Yes = 4 points Patients Age and Points Patients Age and Points 225 years = 0 points 41-45 years = 4 points 31-35 years = 2 points 56-60 years = 7 points 56-60 years = 7 points		

PA Type	Criteria	PA Approval Length	Worked By
Stadol Nasal Spray (Butorphanol) PRESCRIBER MUST REQUEST PA PHONE OR FAX	 PA requirements Authorized for migraine pain at a maximum of 2 vials per month (24 vials per year) Authorized for control of short term pain at a maximum of 1 vial per month (12 vials per year) Initial dispensing of one vial per 30-day period does not require prior authorization Service Code/Units Diagnosis of migraines allows for 72 units per year. Any other short term pain diagnosis only allows for 36 units per year (12 x 3ml vials) 	1 year	Pharmacy Tech
	Purpose Limit use to short term pain management only Limit number of units dispensed based upon the use of medication Applicability		

PA Type	Criteria	PA Approval Length	Worked By
	 Limited to 2 vials per month for migraine pain, and one 1 vial per month for other short-term pain. 		

PA Type	Criteria	PA Approval Length	Worked By
Synagis	PA Requirements	Approved	Pharmacy
	 Patient is less than 24 months and has Chronic Lung Disease. 	through April	Tech or
PRESCRIBER	 Patient is less than 12 months with a gestational age of < 28 weeks. 	30 th .	escalate to
MUST	 Patient is less than 6 months with a gestational age of < 32 weeks. 		Clinical
REQUEST PA	 Patient is 4-6 months with a gestational age of 33-36 weeks with a risk factor. 	If requestor	RPh to
	 Patient is < 3 months with a gestational age of < 36 weeks. 	calls in	review for
FAXES ONLY	 Other special circumstances may be considered. Escalate to supervisor. 	October, then	"other
		6 doses may	diagnoses"
	Approved Diagnosis	be approved.	or "other
	 Chronic Lung Disease 		risk
	 Cardiac Surgery 	If the	factors"
	 Cystic Fibrosis 	requestor	
	 Bronchopulmonary Dysplasia 	calls in	
	 Wilson-Mikity Syndrome 	November,	
	 Congenital Heart Disease 	then 5 doses	
	 Concomitant medical problems (< 28 weeks GA and < 1 yr old) 	may be	
	 Interstitial Pulmonary Fibrosis 	approved.	
	 Oxygen Use within 6 months 		
	 Others considered – escalate to supervisor. 	December – 4	
	1	doses	
	Risk Factors	January – 3	
	School age siblings	doses	
	 Multiple Births 	February – 2	
	 Crowding in the home 	doses	
	 Neurologic Disease 	March – 1	
	 Day-care attendance 	dose	
	 CLD Treatment in last 6 months 		
	 Exposure to tobacco smoke in the home 	50mg and	
	 Distance to/availability of hospital care 	100mg vials	
	 Others considered – escalate to supervisor. 	may be	
		approved at	
	**Usual dosage is six (6) monthly injections during the Respiratory Syncytial Virus (RSV)	the same	
	season of October 1 st through April 30 th . Administration of a seventh (7 th) dose will require	time.	
	separate prior authorization. This can be approved if the physician deems it is necessary		